Acadia Pharmaceuticals Inc (NASDAQ: ACAD). Extremely important positive changes in investment behavior have recently occurred: positive upside/downside volume developed, the stock’s recent price rise disrupted its longer term downtrend, and its shorter term price trend turned up.
Acadia Pharmaceuticals Inc (NASDAQ: ACAD). Slight positive changes in fundamentals have recently occurred: significant quarterly sales acceleration occurred.
In light of these very positive signals we are reviewing our current Overall Rating of D. We would view the shares with optimism pending completion of this review in the next several days.
Current PriceTarget Research Rating
With future capital returns forecasted to be above the cost of capital, ACAD is expected to be a major Value Builder.
Acadia Pharmaceuticals has a current Value Trend Rating of D (Negative). This rating combines very contradictory signals from two proprietary PTR measures of a stock’s attractiveness. Acadia Pharmaceuticals has a very low Appreciation Score of 6 but a good Power Rating of 80, producing the Negative Value Trend Rating.
Recent Price Action
Acadia Pharmaceuticals Inc (NASDAQ: ACAD) stock closed at $30.13 on 12/19/23 after a large increase of 3.8%. Moreover, trading volume in this advance was unusually high at 153% of normal. The stock has risen 42.9% during the last week and has been strong relative to the market over the last nine months.
Be the first to comment